Ribonuclease H2 mutations induce a cGASSTING-dependent innate immune response

Citation for published version:

Digital Object Identifier (DOI):
10.15252/embj.201593339

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
EMBO Journal

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response

Karen J Mackenzie¹, Paula Carroll³, Laura Lettice³, Žygimantas Tarnauskaitė², Kaalak Reddy¹, Flora Dix¹, Ailsa Revuelta¹, Erika Abbondati², Rachel E Rigby¹‡, Björn Rabe¹‡, Fiona Kilanowski¹, Graeme Grimes¹, Adeline Fluteau¹, Paul S Devenney¹, Robert E Hill¹, Martin AM Reijns¹ & Andrew P Jackson¹,*

Abstract

Aicardi–Goutières syndrome (AGS) provides a monogenic model of nucleic acid-mediated inflammation relevant to the pathogenesis of systemic autoimmunity. Mutations that impair ribonuclease (RNase) H2 enzyme function are the most frequent cause of this autoinflammatory disorder of childhood and are also associated with systemic lupus erythematosus. Reduced processing of either RNA:DNA hybrid or genome-embedded ribonucleotide substrates is thought to lead to activation of a yet undefined nucleic acid-sensing pathway. Here, we establish Rnaseh2a¹⁺⁄⁺/A174T knock-in mice as a subclinical model of disease, identifying significant interferon-stimulated gene (ISG) transcript upregulation that recapitulates the ISG signature seen in AGS patients. The inflammatory response is dependent on the nucleic acid sensor cyclic GMP-AMP synthase (cGAS) and its adaptor STING and is associated with reduced cellular ribonucleotide excision repair activity and increased DNA damage. This suggests that cGAS/STING is a key nucleic acid-sensing pathway relevant to AGS, providing additional insight into disease pathogenesis relevant to the development of therapeutics for this childhood-onset interferonopathy and adult systemic autoimmune disorders.

Keywords  Aicardi–Goutières syndrome; autoinflammation; cGAS-STING; ribonuclease H2

Subject Categories  Immunology

DOI 10.15252/embj.201593339 | Received 23 October 2015 | Revised 20 January 2016 | Accepted 22 January 2016

Introduction

Nucleic acid sensing is a key element of antimicrobial immunity (Wu & Chen, 2014). Diverse nucleic acid sensors act as pattern recognition receptors (PRRs), initiating innate immune responses necessary to protect against pathogens containing a diverse range of nucleic acid species (Wu & Chen, 2014). Such innate immune activation, arising from sensing of cellular nucleic acids, is also implicated in autoimmune disease, most notably systemic lupus erythematosus (SLE) (Wahren-Herlenius & Dorner, 2013).

The autoinflammatory disorder Aicardi–Goutières syndrome (AGS) has provided important insights into mechanisms underlying nucleic acid-mediated inflammation (Crow & Manel, 2015). AGS typically presents in infancy following a period of normal development, with sterile pyrexia, irritability, seizures and loss of developmental milestones (Crow & Livingston, 2008). Persisting severe physical and intellectual disability is frequent, and extra-neurological features can include vasculitic skin lesions (Crow & Livingston, 2008; Crow et al, 2015). Increased type 1 interferon activity is most reliably detected during the initial stages of the disease (Crow et al, 2015). However, upregulated interferon-stimulated gene (ISG) transcripts in blood have proven to be the most robust diagnostic biomarker in AGS patients, and an “ISG signature” often persists long after the initial stages of disease (Rice et al, 2013; Crow et al, 2015).

Although AGS is a monogenic disorder, it is genetically heterogeneous, with seven genes implicated to date, encoding several nucleic acid processing enzymes and a cytosolic nucleic acid sensor. These comprise the RNASEH2A, RNASEH2B and RNASEH2C proteins of the RNase H2 endonuclease complex (Crow et al, 2006b) as well as TREX1, SAMHD1, ADAR and IFIH1 (Crow et al, 2006a; Rice et al, 2009, 2012, 2014). Heterozygous mutations in the three RNase H2 genes (Günther et al, 2015) and TREX1 (Lee-Kirsch et al, 2007) are also associated with systemic lupus erythematosus.

Partial loss-of-function biallelic mutations in the RNase H2 genes are the major cause of AGS, accounting for over half of all cases (Crow et al, 2015). RNase H2 is ubiquitously expressed and functions alongside RNase H1 to degrade cellular RNA:DNA heteroduplexes. Although the exact in vivo substrates of these nucleases remain to be identified, they are thought to act on RNA:DNA hybrids such as those arising during nuclear DNA replication and R-loop formation (Cerritelli & Crouch, 2009). Unlike RNase H1, RNase H2 also cleaves and initiates the removal of single ribonucleotides

1 MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK
2 Roslin Institute, The University of Edinburgh, Edinburgh, UK
*Corresponding author. Tel: +44 131 651.8500; Fax: +44 131 467 8456; E-mail: andrew.jackson@igmm.ed.ac.uk
‡Present address: MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC WIMM University of Oxford, Oxford, UK
¹Present address: Institute of Biochemistry, Christian-Albrechts-University of Kiel, Kiel, Germany

© 2016 The Authors. Published under the terms of the CC BY 4.0 license
embedded in DNA (Eder et al, 1993; Rydberg & Game, 2002), a process known as ribonucleotide excision repair (REK) (Sparks et al, 2012). RNase H2 is essential for mammalian genome stability, with complete loss of RNase H2 resulting in embryonic lethality (Reijns et al, 2012; Hiller et al, 2012).

Intracellular accumulation of aberrant nucleic acid species is believed to trigger intrinsic nucleic acid sensors initiating auto-immunity in AGS (Crow & Manel, 2015). Trex1−/− and Adar1−/− mouse models have, respectively, implicated the cGAS-STING pathway (Ablasser et al, 2014; Ahn et al, 2014a; Gray et al, 2015; Gao et al, 2015) and MDA5/IFIH1 (Liddicoat et al, 2015) pathways in driving immune activation. However, to date, an immune phenotype in mice has not been described for mutations in any of the RNase H2 subunits. It therefore remains to be determined whether a similar phenotype is seen in mice lacking all three RNase H2 subunits in a hypomorphic RNase H2 mouse model for AGS patients. We present evidence that this is dependent on the cGAS/STING pathway, consistent with PRR sensing of cell-intrinsic nucleic acids in RNase H2-deficient cells.

**Results**

A hypomorphic RNase H2 mouse model for Aicardi–Goutières syndrome

A mouse model was created by targeted knock-in of the A174T missense mutation (c.520G>A) into exon 7 of Rnaseh2b in mouse embryonic stem cells using homologous recombination (Fig 1A–D and Appendix Fig S1). A C57BL/6J congenic Rnaseh2bA174T/A174T mouse line was established using these cells, orthologous to the most common pathogenic mutation found in AGS patients. We demonstrate that this is dependent on the cGAS/STING pathway, consistent with PRR sensing of cell-intrinsic nucleic acids in RNase H2-deficient cells.

We next investigated whether the observed ISG induction was directly attributable to reduced RNase H2 activity. To address this, we examined cells from a second independent mouse line carrying a null allele of Rnaseh2b (Rnaseh2bΔ174T) derived from the UECOMM knockout-first Rnaseh2bm1al allele, from which exon 5 of Rnaseh2b had been excised by Cre recombinaise. Given the early embryonic lethality of Rnaseh2b−/− mice (Reijns et al, 2012), mouse embryonic fibroblasts (MEFs) were generated on a p53−/−, p53−/−/C0 and Samhd1−/−/C0 background. Hereafter, we refer to the resulting Rnaseh2b−/−/p53−/− and Rnaseh2b−/−/p53−/−/Samhd1−/− mice simply as Rnaseh2b−/− and Rnaseh2b−/−/Samhd1−/−, respectively. Loss of RNase H2 activity in Rnaseh2b−/− cells was confirmed (Fig 3A).

Significant upregulation of ISG transcripts was again apparent, on comparing six independent Rnaseh2b−/− MEF lines with four Rnaseh2b−/− control MEF lines (Fig 3B and Appendix Fig S2A). To further characterise the nature of the response, two of the Rnaseh2b−/− MEF lines with stronger ISG upregulation were compared to control lines by gene expression microarray (Fig 3C and Appendix Table S1). Of the 29 upregulated genes achieving genome-wide significance, 17 were documented ISGs and activation of non-ISG immune response pathways was not evident. In particular, there was significant induction of two ISG encoding proinflammatory cytokines: Ccl5 (P = 0.0067) and Cxcl10 (P = 0.039). Upregulation of both transcripts was confirmed by RT-PCR, and ELISA of culture supernatants from all six Rnaseh2b−/− lines demonstrated significantly increased CCL5 and CXCL10 secretion (Fig 3D and E, 2015). Since an ISG transcriptional response is the most robust biomarker of inflammation in human patients (Rice et al, 2013), we performed RT–qPCR for a panel of AGS-relevant ISGs on RNA extracted from adult Rnaseh2bA174T/A174T mouse tissues. A broad upregulation of ISGs was detected in heart (Fig 2A) along with significant induction of a subset of ISGs in the kidney (Fig 2B), but without any ISG response evident in brain (Fig 2C). The twofold to fourfold induction of ISGs we observed in Rnaseh2bA174T/A174T heart tissue is comparable to the fourfold to sevenfold induction seen in Samhd1−/− mouse tissue (Rehwinkel et al, 2013). While an overt inflammatory phenotype is seen in Trex1−/− mice (Morita et al, 2004; Gall et al, 2012), pathological signs of neuroinflammation are not evident, although ISG upregulation in brain tissue can be detected (Pereira-Lopes et al, 2013). Given that the autoinflammatory process appears to initiate in the Trex1−/− heart (Gall et al, 2012), there are similarities between the pattern of inflammation in Trex1−/− mice and the ISG tissue expression pattern in Rnaseh2bA174T/A174T mice.

A proinflammatory response in Rnaseh2b−/− MEFs

We next investigated whether the observed ISG induction was significantly reduced to 30% activity in Rnaseh2b−/− MEFs (Fig 1F and G) and 49% ± 3% activity in Rnaseh2bA177T/A177T MEFs (Fig 1F and H), assessed against an embedded ribonucleotide substrate. More pronounced reduction in the mouse cells may be explained by the presence of a neomycin selection cassette between exon 6 and 7, causing reduced Rnaseh2b transcript levels (~60% of wild type; data not shown).

Despite marked impairment of RNase H2 activity, Rnaseh2bA177T/A177T mice had no overt phenotype and remained healthy when aged. Full pathological examination of brain, liver, heart, lungs, thymus, spleen, gastrointestinal tract, kidneys, skin and tongue from mice (n = 9) did not detect histological features of inflammation, infection or neoplasia at 1 year (data not shown). In particular, there was no evidence of intracranial calcification, leukodystrophy, chilblain vasculitis or cardiomyopathy, clinical features associated with AGS in humans (Crow et al, 2015). Notably, histopathological signs of inflammation are also not evident in Samhd1−/− mice, although activation of innate immune signalling does occur, with ISG upregulation evident (Behrendt et al, 2013; Rehwinkel et al, 2013). We therefore investigated whether this was also the case in Rnaseh2bA174T/A174T mice.

**ISG upregulation is present in tissues from Rnaseh2bA174T/A174T mice**

Since an ISG transcriptional response is the most robust biomarker of inflammation in human patients (Rice et al, 2013), we performed RT–qPCR for a panel of AGS-relevant ISGs on RNA extracted from adult Rnaseh2bA174T/A174T mouse tissues. A broad upregulation of ISGs was detected in heart (Fig 2A) along with significant induction of a subset of ISGs in the kidney (Fig 2B), but without any ISG response evident in brain (Fig 2C). The twofold to fourfold induction of ISGs we observed in Rnaseh2bA174T/A174T heart tissue is comparable to the fourfold to sevenfold induction seen in Samhd1−/− mouse tissue (Rehwinkel et al, 2013). While an overt inflammatory phenotype is seen in Trex1−/− mice (Morita et al, 2004; Gall et al, 2012), pathological signs of neuroinflammation are not evident, although ISG upregulation in brain tissue can be detected (Pereira-Lopes et al, 2013). Given that the autoinflammatory process appears to initiate in the Trex1−/− heart (Gall et al, 2012), there are similarities between the pattern of inflammation in Trex1−/− mice and the ISG tissue expression pattern in Rnaseh2bA174T/A174T mice.
RNase H2 complex levels and enzymatic activity are reduced in RNase2b<sup>4174T/A174T</sup> mouse and RNASEH2b<sup>4174T/A177T</sup> AGS patient cells.

A Targeted mutagenesis of the RNase2b gene. Top: A 7-kb region of the RNase2b genomic locus; black boxes, exons 6 (ex6) and 7 (ex7). Middle: NotI/Sall restriction fragment of the targeting construct, comprising 4.5 kb of genomic DNA and a neomycin selection cassette (Neo) flanked by loxP sites (triangles). (Bottom) Targeted locus containing ex6 with the c.520G>A mutation (ex7*). Red arrowheads, primers used to confirm correct targeting. Red bar, 400-bp probe for Southern blotting.

B Southern blotting confirms successful targeting. Introduction of an additional EcoRI site results in a 0.4-kb restriction fragment detectable by Southern for targeted ES cells (A174T/+), but not for parental DNA (+/+).

C Capillary sequencing for RNase2b<sup>T/A</sup>, RNase2b<sup>A174T</sup>, and RNase2b<sup>A174T/A177T</sup> DNA confirmed the presence of the introduced missense mutation.

D Mouse genotyping by multiplex PCR. Top: A 221-bp PCR product is present in wild-type mice (+/+); the RNase2b<sup>A174T/A177T</sup> allele (also) gives a 460-bp product. Bottom: Position of forward (x) and reverse primers (y, z).

E Immunoblotting demonstrates depletion of all three RNase H2 protein subunits in RNase2b<sup>A177T/A177T</sup> MEFs and RNASEH2b<sup>A177T/A177T</sup> LCLs. Representative of three independent experiments.

F Schematic showing enzyme activities attributed to RNase H1 and RNase H2 (DNA blue, RNA red).

G, H Enzyme activity in LCLs from two independent healthy controls and an AGS patient homozygous for the RNASEH2b<sup>A177T/A177T</sup> mutation. Enzyme activity normalised to average activity of control lines. Three independent experiments; error bars represent SEM. ***P < 0.001, two-tailed t-test (n = 3 RNase2b<sup>A177T/A177T</sup> and n = 3 RNase2b<sup>T/A</sup> control MEF lines). (H) RNase H2 activity in LCLs from two independent healthy controls and an AGS patient homozygous for the RNASEH2b<sup>A177T/A177T</sup> mutation. Enzyme activity normalised to average activity of control lines. Three independent experiments, error bars represent SEM. ***P < 0.001 versus either control, two-tailed t-test.

Source data are available online for this figure.
and Appendix Fig S2B). Notably, these cytokines have previously been implicated in AGS neuroinflammation in humans (van Heteren et al., 2008; Takanohashi et al., 2013; Cuadrado et al., 2015). We therefore concluded that impaired RNase H2 activity in vitro and in vivo results in a similar inflammatory response to that observed in patients with AGS, and like for Trex1 deficiency (Gall et al., 2012) is present in non-immune cells.

ISG activation is dependent on the cGAS-STING nucleic acid-sensing pathway

We next sought to determine the nucleic acid-sensing pathway responsible for ISG induction in Rnaseh2b<sup>A174T/A174T</sup> cells. Three pathways have recently been implicated in the sensing of RNA: DNA hybrids: TLR9 (Rigby et al., 2014), cGAS-STING (Mankan et al., 2014) and the NLRP3 inflammasome (Kailasan Vanaja et al., 2014). We therefore postulated that one of these nucleic acid sensors would be responsible for the ISG signature, given that RNase H2 is the major enzyme degrading RNA:DNA hybrids in mammalian cells (Büsen, 1980; Reijns et al., 2012). However, as IL-1β and IL-18 were both undetectable in culture supernatants from Rnaseh2b<sup>−/−</sup> cells (data not shown), an inflammasome-mediated response was unlikely. While the observed ISG induction would be consistent with TLR9 activation, signalling is impaired by deficient proteolytic processing of the receptor in MEFs (Ewald et al., 2008), and we therefore prioritised assessment

Figure 2. Increased ISG expression in tissues from Rnaseh2b<sup>A174T/A174T</sup> mice.
A Transcript levels of multiple ISGs are significantly elevated in heart.
B Transcript levels of a subset of ISGs are significantly increased in kidney.
C No ISG upregulation is evident in the brain.

Data information: ISG transcript levels determined by RT–qPCR normalised to transcript levels of the housekeeping gene HPRT (Oas1a was undetectable in brain). Each data point represents the mean of technical replicates of tissue RNA from a single mouse. n = 9 nine-month-old Rnaseh2b<sup>A174T/A174T</sup> mice and n = 4 age-matched control wild-type C57BL/6j mice. Horizontal line, mean; error bars, SEM. *P < 0.05, **P < 0.01, two-tailed t-test.
of the cGAS-STING pathway. We performed siRNA depletion of cGAS in *Rnaseh2b*−/− MEFS and found that cGAS depletion significantly abrogated the ISG response and CCL5 production (Fig 4A). siRNA depletion of STING, the adaptor associated with cGAS sensing, also significantly reduced ISG induction and CCL5 secretion (Fig 4A), implicating the cGAS/STING-sensing pathway in innate immune activation in *Rnaseh2b*−/− cells. The siRNA knock-down was specific to cGAS and STING, respectively (Fig 4A), and cells remained fully responsive to poly(I:C) (Appendix Fig S3).

To substantiate that cGAS is required for ISG induction, CRISPR/Cas9 genome editing was performed to knock out the cGAS gene in *Rnaseh2b*−/− MEFS. *Rnaseh2b*−/− MEF clones in which cGAS deletion had not occurred were also identified, to act as experimental controls. While ISG transcript upregulation and cytokine production...
**Figure 4.** The EMBO Journal

Ribonuclease H2 mutations and the cGAS-STING pathway

Karen J Mackenzie et al

A

**CCL5**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>Luciferase siRNA</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>cGAS siRNA</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>STING siRNA</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**% CCL5 relative to luciferase control**

<table>
<thead>
<tr>
<th>Luciferase siRNA</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>cGAS siRNA</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>STING siRNA</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

B

**CCL5**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Luciferase siRNA</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>cGAS siRNA</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>STING siRNA</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

C

**CXCL10**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>Luciferase siRNA</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>cGAS siRNA</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>STING siRNA</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

D

**IFIT1**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>cGAS<strong>cgas</strong></th>
<th>Rnaseh2b**</th>
<th>Rnaseh2b**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sting**+/+**</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**IFIT3**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>cGAS<strong>cgas</strong></th>
<th>Rnaseh2b**</th>
<th>Rnaseh2b**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sting**+/+**</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**OAS1A**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>cGAS<strong>cgas</strong></th>
<th>Rnaseh2b**</th>
<th>Rnaseh2b**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sting**+/+**</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**CXCL10**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>cGAS<strong>cgas</strong></th>
<th>Rnaseh2b**</th>
<th>Rnaseh2b**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sting**+/+**</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**CCL5**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>cGAS<strong>cgas</strong></th>
<th>Rnaseh2b**</th>
<th>Rnaseh2b**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sting**+/+**</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**IFI44**

Expression normalised to HPRT

<table>
<thead>
<tr>
<th>cGAS<strong>cgas</strong></th>
<th>Rnaseh2b**</th>
<th>Rnaseh2b**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sting**+/+**</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

E

**IFIT1**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**IFIT3**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**OAS1A**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**CXCL10**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**CCL5**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

F

**IFIT1**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**IFIT3**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**OAS1A**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**CXCL10**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>

**CCL5**

Expression in heart normalised to HPRT

<table>
<thead>
<tr>
<th>Sting**+/+**</th>
<th>+</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
</table>
performed complementation experiments in RNase H2 null cells, to
investigate which enzymatic activity was associated with the pro-
inflammatory response. RNaseh2b–/– cells were complemented by retroviral transduction of either Rnaseh1 or RNaseh2b, respectively, to reconstitute cellular RNase H activity or RNase H plus RER activity. Overexpression of RNase H1 in RNaseh2b–/– cells restored cellular enzyme activity against RNA:DNA hybrids to 81 ± 10% of the level seen in RNaseh2b+/+ cells (Fig 5A), but did not alleviate DNA damage (Fig 5B and C). Complementation with RNaseh2b reconstituted activity against both types of substrates (Fig 5A) and also returned DNA damage to levels seen in RNaseh2b+/+ cells (Fig 5B and C). Reconstitution with RNaseh2b was able to reduce cytokine and ISG responses close to wild-type levels (Fig 5D–F), while RNaseh1 complementation did not (Fig 5D–F). While some reduction was seen in CCL10, ISG expression in RNaseh1 complemented cells was otherwise the same, if not greater than, in parental RNaseh2b–/– cells. cGAS-dependent ISG induction in RNaseh2b–/– cells is therefore associated with DNA damage and loss of RNase H2-specific activity, rather than an overall reduction in cellular activity against RNA:DNA hybrids.

Discussion
Here, we establish that RNase H2 deficiency leads to a proinflamma-
tory response which is dependent upon the cGAS/STING pathway. The resulting ISG transcriptional response and induction of pro-
inflammatory cytokines are consistent with cell-intrinsic innate
immunogenicity. ISG activation varied between tissues, which may explain why such transcriptional changes were not reported

(CCL5 and CXCL10) were still observed in such control cells, both
were abrogated in CRISPR/Cas9 targeted Rnaseh2b+/–/–Cas–/– cells (Fig 4B–D), establishing that the innate immune activation found in
Rnaseh2b+/–/– MEFs is dependent on cGAS.

To determine whether ISG induction was dependent on the
cGAS/STING-sensing pathway in vivo, we intercrossed Rnaseh2b+/–/–/– and Sting+/– mice. We found that ISG transcript
levels from Rnaseh2b+/–/–/–/– Sting+/– heart tissue were signifi-
cantly reduced compared to Rnaseh2b+/–/–/– Sting+/–/– controls (Fig 4E), while no significant reduction was observed when comparing
Rnaseh2b+/–/–/– Sting+/– and Rnaseh2b+/–/–/– Sting+/–/– controls (Fig 4F). Hence, a STING-dependent ISG response also occurs in vivo in Rnaseh2b+/–/–/–/– mice, implicating the cGAS/STING
pathway in the ISG induction observed in Rnase H2 AGS patients.

Loss of RNase H2-specific activity results in ISG induction
Finally, the fact that both dsDNA (Sun et al, 2013; Gao et al, 2013)
and RNA:DNA hybrids (Mankan et al, 2014) can bind and activate
the cytoplasmic nucleic acid sensor cGAS prompted us to consider
the origin of the cGAS ligand present in RNase H2-deficient cells.
Abrogated RNase H2 function could give rise to cytosolic accumula-
tion of RNA:DNA heteroduplexes as a consequence of reduced RNA:
DNA degradation of structures such as R-loops or active retro-
elements/endogenous retroviruses (Chon et al, 2013; Rigby et al,
2014; Moelling & Broecker, 2015). Alternatively, cytoplasmic DNA with embedded ribonucleotides may accumulate as a consequence of impaired RER that resulted in genome instability (Reijns et al,
2012; Hiller et al, 2012). To address these possibilities, we
performed complementation experiments in RNase H2 null cells, to
evaluate which enzymatic activity was associated with the pro-
inflammatory response.

RNaseh2b+/–/–/– cells were complemented by retroviral transduction of either Rnaseh1 or RNaseh2b, respectively, to reconstitute cellular
RNase H activity or RNase H plus RER activity. Overexpression of
RNase H1 in RNaseh2b+/–/– cells restored cellular enzyme activity
against RNA:DNA hybrids to 81 ± 10% of the level seen in
RNaseh2b+/–/–/– cells (Fig 5A), but did not alleviate DNA damage (Fig 5B and C). Complementation with RNaseh2b reconstituted activity
against both types of substrates (Fig 5A) and also returned DNA
damage to levels seen in RNaseh2b+/–/– cells (Fig 5B and C). Reconsti-
tution with RNaseh2b was able to reduce cytokine and ISG responses close to wild-type levels (Fig 5D–F), while RNaseh1 complementation did not (Fig 5D–F). While some reduction was seen in CCL10, ISG expression in RNaseh1 complemented cells was otherwise the same, if not greater than, in parental RNaseh2b+/–/–/– cells. cGAS-dependent ISG induction in RNaseh2b+/–/–/– cells is therefore associated with DNA damage and loss of RNase H2-specific activity, rather than an overall reduction in cellular activity against RNA:DNA hybrids.

Discussion
Here, we establish that RNase H2 deficiency leads to a proinflamma-
tory response which is dependent upon the cGAS/STING pathway. The resulting ISG transcriptional response and induction of pro-
inflammatory cytokines are consistent with cell-intrinsic innate
immunogenicity. ISG activation varied between tissues, which may explain why such transcriptional changes were not reported
Figure 5.

The EMBO Journal
Ribonuclease H2 mutations and the cGAS-STING pathway  Karen J Mackenzie et al
previously in Rnaseh2b<sup>−/−</sup> or Rnaseh2b<sup>rnas/rnas</sup> embryos (Reijns et al., 2012; Hiller et al., 2012). The precise factors determining tissue-specific cGAS activation are currently unclear, but could include the sensitivity of the cGAS/STING pathway in particular cell types, their level of cell proliferation, the rate of accumulation of immunogenic nucleic acids and the counteracting influences of cellular processes degrading such nucleic acids.

Despite tissue-specific ISG upregulation, Rnaseh2b<sup>A174T/A174T</sup> mice have a subclinical phenotype without any overt inflammatory pathology, and so, like all other AGS mouse models do not recapitulate the neuroinflammation seen in human AGS patients (Rabe, 2013; Behrendt & Roers, 2014). It will therefore be important to confirm that the innate immune pathways implicated in Trex1, Adar1 and now Rnase H2 deficiency, through the use of mouse models, are also relevant to the human autoinflammatory phenotype in AGS patients in whom these genes are affected. Samhd1<sup>−/−</sup> mice, like Rnaseh2b<sup>A174T/A174T</sup> mice, display an ISG response in the absence of detectable pathology (Behrendt et al., 2013; Rehwinkel et al., 2013). In contrast a strong ISG response in Adar1 null or editing-deficient mice is associated with embryonic lethality (Mannoni et al., 2014; Liddicoat et al., 2015; Pestal et al., 2015), and with autoinflammatory cardiomyopathy and multi-tissue involvement in Trex1<sup>−/−</sup> mice (Morita et al., 2004; Stetson et al., 2008; Gall et al., 2012). The variation in severity between different AGS gene mouse models remains unexplained, although it may be meaningful that mutations in human RNASEH2B are associated with the least severe disease course, with AGS onset generally in infancy, in contrast to the prenatal/neonatal onset more commonly seen in TRESX1 patients (Crow et al., 2015). Also, additional triggers, such as viral infection, have been proposed as relevant to the pathogenesis of AGS (Crow & Manel, 2013). Reports of marked phenotypic variability in sibling pairs with identical RNASEH2B or RNASEH2C mutations (Vogt et al., 2013; Tüngler et al., 2014) are consistent with the possibility of such environmental factors impacting on disease severity. The Rnaseh2b<sup>A174T/A174T</sup> mouse and other models provide an opportunity for future investigation of these aspects.

Identification of the precise source of the immunogenic nucleic acids responsible for the inflammatory phenotype remains central to providing further mechanistic insight. Dependence of the ISG response in RNase H2- and Trex1-deficient mouse cells on the cGAS/STING pathway suggests that accumulation of cytoplasmic DNA is common to both TREX1 and Rnase H2 AGS, given that DNA is the canonical ligand for cGAS (Sun et al., 2013; Gao et al., 2013). Our complementation experiments would favour this possibility, as normalising cellular enzymatic activity against RNA:DNA hybrids does not rescue the proinflammatory response. However, immunogenic RNA:DNA hybrids cannot be completely excluded, given that some hybrids might be specifically degraded by the RNase H2 enzyme (Chon et al., 2013), although the mechanism for such differential substrate specificity for RNase H1 and H2 enzymes is currently unclear.

So far, we have been unable to ascertain whether cytoplasmic double-stranded nucleic acids accumulate in RNase H2-deficient cells. However, given that impaired RER causes reduced genome stability, DNA fragments resulting from DNA strand breaks are a potential origin of immunogenic cytoplasmic DNA (Ahn et al., 2014b; Hartlova et al., 2015; Shen et al., 2015), while an alternative source could be reverse-transcribed retroelements, which are known to be activated upon DNA damage (Farkash & Luning Prak, 2006). Irrespective of the chemical nature of the ligand, our observation that cGAS plays a central role in the ISG response in Rnase H2 deficiency provides further impetus for defining the source of the immunogenic nucleic acids. While cytoplasmic DNA was first detected in 2007 in Trex1<sup>−/−</sup> cells, even here the precise origin still remains elusive, with conflicting evidence supporting either endogenous retroviruses/retroelements (Stetson et al., 2008) or genome instability (Yang et al., 2007). Purification of the responsible immunostimulatory nucleic acids could provide the solution; however, the specific isolation of such low-abundant cytoplasmic nucleic acids remains a formidable technical challenge. This has precluded a definitive answer to date, but may be aided by implicating cGAS as the nuclear acid sensor binding immunogenic nucleic acids in both Trex1- and Rnase H2-deficient cells, informing potential future biochemical strategies.

In summary, our findings implicate the cGAS-STING pathway in RNase H2 AGS and, together with the previously attributed role in Trex1 deficiency, suggest it is the most common signalling pathway driving inflammation in AGS, relevant also to the pathogenesis of SLE (Lee-Kirsch et al., 2007; Günther et al., 2015). Targeting this pathway therefore represents a relevant therapeutic strategy for the treatment of this childhood interferonopathy and related adult-onset autoimmune conditions.

**Materials and Methods**

**Generation of Rnaseh2b<sup>A174T</sup> ES cells**

Gap repair was used to retrieve a genomic fragment of 4.5 kb from BAC bMQ454F14 (Source Bioscience Lifesciences), which included exon 6 and 7 of the mouse Rnaseh2b locus (nucleotides 62977197-62981727 of Chr14, Ensembl release 64). Subsequent bacterial recombination was used to insert a neomycin cassette flanked by loxP sites between exon 6 and 7, generating a targeting vector with two external homology arms of 2.8 kb and 1.7 kb. A point mutation c.520G>A (A174T) was inserted into exon 7 of mouse Rnaseh2b by site-directed-mutagenesis (Quick-change, Agilent Technologies). After linearisation and vector backbone removal by digestion with NotI and SalI, and electrophoresis/purification by Elutrap, the targeting cassette was electroporated into 129/OLA E14Tg2AIV embryonic stem cells. Southern blotting and long-range PCR were used to identify correctly targeted clones. Capillary sequencing was performed to ensure the presence of the c.520G>A mutation and absence of other coding changes. The ES cell clone was karyotyped before injection into C57BL/6J mouse blastocysts.

**Mice**

**Rnaseh2b<sup>A174T</sup>**

Male chimeras resulting from blastocyst injection with Rnaseh2b<sup>A174T/+</sup> ES cells were crossed to C57BL/6J females, giving rise to heterozygous Rnaseh2b knock-in mice carrying the A174T mutation (Rnaseh2b<sup>rnas2-hgu-A174T</sup>), elsewhere referred to as Rnaseh2b<sup>A174T</sup> mice. These were backcrossed to F11 on the C57BL/6J.
background to establish congenicity and subsequently maintained as a homozygous mutant line. C57Bl/6j control mice were bought in at 4–6 weeks of age from the same source as those used in backcrossing, to ensure genetic matching to a level of > 99.97% identity. All mice were housed in the same facility in the same room in conventional cages and fed the same water and food until they were analysed. Murine data were analysed unblinded to geno-

**Rnaseh2btm1d**

Knockout-first Rnaseh2b mice were generated by blastocyst injection of the Rnaseh2btm1d(EUCOMM)Wtsi C57BL/6j ES cell clone EPD00874_A02 (EUCOMM ID: 24441) and crossing of male chimeras to C57BL/6j females. The Rnaseh2b<sup>tm1d</sup> allele, in which exon 5 is deleted, was generated by crossing of Rnaseh2b<sup>tm1d</sup>+ mice to mice with ubiquitous expression of FLPe recombinase to delete the genetrap cassette. Rnaseh2b<sup>tm1d/+</sup> offspring were subsequently crossbred to C57Bl/6j mice (a kind gift from DJ Kleinjan, University of Edinburgh), containing a CAGGS-Cre construct in which Cre recombinase is under control of a chicken β-actin promoter (Araki et al., 1995; Kleinjan et al., 2006) to excise Rnaseh2b exon 5. The resulting Rnaseh2b<sup>tm1d/+</sup> (Rnaseh2b<sup>−/−</sup>) mice were maintained on the C57BL/6j background. The phenotype of Rnaseh2b<sup>tm1d/+</sup> embryos was indistinguishable from that previously described for Rnaseh2b<sup>202X/E202X</sup> embryos (Reijns et al., 2012).

**Other strains**

Trp53<sup>−/−</sup>/J mice on the C57BL/6j background have been described previously (Jacks et al., 1994) and were kindly provided by Andrew Wood, University of Edinburgh. Interbreeding with Rnaseh2b<sup>tm1d/+</sup> mice was used to generate Rnaseh2b<sup>+/+ p53<sup>+/−</sup></sup> and Rnaseh2b<sup>−/− p53<sup>−/−</sup></sup> MEFs.

Sting/Mpys<sup>−/−</sup> mice on the C57BL/6j background have been described previously (Jin et al., 2011) and were kindly provided by Jan Rehwinkel, University of Oxford, with the consent of John Cambier, University of Colorado SOM and National Jewish Health. Interbreeding with Rnaseh2b<sup>1A174T/1A174T</sup> mice generated Rnaseh2b<sup>1A174T/1A174T Sting<sup>−/−</sup></sup> mice.

Mbh21d1/cGas<sup>−/−</sup> MEFs derived from C57BL/6jNTac-Mb21d1<sup>tm1a(EUCOMM)Hmgk</sup>/icsOrl mice were a kind gift from Jan Rehwinkel, Oxford University. These mice were originally obtained from the Institute Clinique de la Souris through the European Mouse Mutant Archive.

All mouse studies were conducted according to UK Home Office regulations under a UK Home Office project licence.

**Genotyping**

DNA was extracted from earclips (boiled in 50 μl 25 mM NaOH, 0.2 mM EDTA for 30 min at 95°C, cooled and then neutralised with 50 μl 40 mM Tris base) or embryos (tail tips treated with DirectPCR Lysis Reagent (Viagen) according to the manufacturer’s instructions). All genotyping PCRs were performed using a multiplex three-primer strategy and Taq ReddyMix PCR Master Mix (Thermo Scientific), as previously described for Rnaseh2b<sup>E202X/E202X</sup> (Reijns et al., 2012) and p53<sup>−/−</sup> (Jacks et al., 1994). For Rnaseh2b<sup>tm1d/+</sup>, Sting/Mpys<sup>−/−</sup> as well as all other primers and product sizes, see Appendix Table S2.

**Generation of murine embryonic fibroblast lines and assessment of innate immune activation**

Independent Rnaseh2b<sup>A174T/A174T</sup> and Rnaseh2b<sup>+/−</sup> MEF lines were generated from individual E13.5 embryos. After removing the head and internal organs, the embryos were mechanically dissociated in growth medium (DMEM, 10% FCS, 50 μl penicillin and 50 μg/ml streptomycin, 0.1 mM β-mercaptoethanol). Resulting suspensions were grown at 37°C, 5% CO2 and 3% O2, and non-adherent cells removed after 24 h. MEFs were subsequently maintained and passaged under the same conditions. Independent Rnaseh2b<sup>−/−</sup>, p53<sup>−/−</sup> and Rnaseh2b<sup>+/−</sup> p53<sup>−/−</sup> MEF lines were similarly generated from individual whole E10.5 embryos. For assessment of ISG upregulation and cytokine production, MEFs were plated at 2 × 10<sup>4</sup> cells per well in 12-well plates. The following day culture medium was replaced with 800 μl of fresh medium. After a further 20 h, the culture medium was replaced for assessment by ELISA to determine CXCL10 and CCL5 concentrations (R&D Systems). RNA was extracted from adherent cells using the RNaseasy kit (Qiagen) as per manufacturer’s instructions and included DNase I treatment. Extracted RNA was stored at −80°C until analysis.

**AGS patient cells**

A lymphoblastoid cell line from an AGS patient with the RNASEH2B-A177T mutation (kindly donated by Professor Yanick Crow, University of Manchester) and non-affected controls were generated from peripheral blood samples by EBV transformation using standard methods. Lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 supplemented with 15% foetal bovine serum, L-glutamine, 50 μl/m penicillin and 50 μg/ml streptomycin at 37°C, 5% CO₂ and normoxic conditions. The A177T/A177T mutation in the patient cell line was validated using Sanger sequencing.

**Immunoblotting**

Whole-cell lysates were prepared by lysing cells in 50 mM Tris (pH 8), 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10% glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for 10 min at 4°C. Lysed cells were then diluted 1:1 with 20 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 10% glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for an additional 10 min, and extracts were cleared by centrifugation (17,000 g, 5 min, 4°C). Equal amounts of proteins from supernatants (concentrations determined using the Bradford method) were separated by SDS-PAGE on NuPAGE Novex Bis-Tris 4–12% protein gels (Thermo Fisher Scientific) and transferred to PVDF membrane. Membranes were blocked in 5% milk in TBS with 0.2% Tween and probed with antibodies raised against mouse or human recombinant RNase H2, as previously described (Reijns et al., 2012), RNASEH2A (TA060706, Origene) or actin (A2066, Sigma).

**RNase H enzyme assays**

Enzyme activity assays were performed using a FRET-based fluorescent substrate release assay, as previously described
GEO

Microarray data were deposited at the Gene Expression Omnibus (GEO) against the background of genes detected on the array. WT MEFs significantly upregulated against Rnaseh2b knockout (q-value < 0.05 and log2FC > 0) were tested for functional enrichment against the background of genes detected on the array. Microarray data were deposited at the Gene Expression Omnibus (GEO)—accession number GSE76942.

siRNA knock-down

MEFs were plated overnight at 2 × 10^4 cells per well in a 24-well plate. The following day cells were transfected with short-interfering RNA (siRNA) oligonucleotides targeting cGAS, STING or designed against Luciferase, using Dharmafect 1 in Opti-MEM reduced serum medium (Thermo Fisher Scientific). Appendix Table S4 lists the oligonucleotide sequences. Transfection medium was replaced with 800 μl complete medium after 6 h, and culture medium was removed 48 h after transfection and used for ELISA analysis. Total RNA was extracted from cells as described above. To assess responsiveness to poly(I:C) following siRNA treatment, cells were further transfected with a final concentration of 10 μg/ml of high molecular weight poly(I:C) (InvivoGen) and culture supernatants assessed 22 h later for CCL5 using ELISA.

CRISPR/Cas9 genome editing

Rnaseh2b^-/- p53^-/- MEFs were electroporated using the neon transfection system (Invitrogen) with vectors based on pSpCas9n (BB)-2A-GFP, a gift from Feng Zhang (Addgene plasmid # 48140), expressing two guide RNAs designed against the coding part of exon 1 of murine cGAS/Mb21d1 (NM_173386.5), using previously described methods (Reijns et al., 2013). Rnaseh2b^-/- p53^-/- cGAS^-/- clones were selected by sizing of PCR products of the targeted region to detect clones in which deletions had occurred; these were subsequently confirmed by Sanger sequencing ensuring out of frame deletions in all alleles. Rnaseh2b^-/- p53^-/- cGAS^-/^- MEF clones were identified in parallel to act as controls. An additional functional assay was performed to confirm inactivation of cGAS by assessing cellular responsiveness to transfected dsDNA (1.33 μg/ml final concentration, ISD naked (InvivoGen)) to ensure the absence or presence of functional cGAS, and 2’3’-cGAMP (2 μg/ml final concentration (InvivoGen)) to confirm the presence of functional STING. Innate immune activation of Rnaseh2b^-/- p53^-/- cGAS^-/^- and Rnaseh2b^-/- p53^-/- cGAS^-/- clones was assessed as described above.

Complementation of Rnase H2 null MEFs

The Rnaseh2b^-/- p53^-/- MEF line used for complementation was previously published and was derived from an E10.5 embryo, resulting from interbreeding Rnaseh2b^-/- p53^-/- mice (Reijns et al., 2012). These cells were infected in the presence of 4 μg/ml polybrene with retroviral supernatant from the Phoenix Ecotropic packaging cell line (Swift et al., 2001) transfected with pMSCVpuro, allowing expression of EGFP, Rnaseh2B (NP_080277) or Rnaseh1 (NP_001273794), and selected for stable integration with 2 μg/ml puromycin. Phoenix cells and pMSCVpuro were a kind gift from Dr. Irena Stancheva, University of Edinburgh.

Immunofluorescence

Parental Rnaseh2b^-/- p53^-/- MEFs, matching Rnaseh2b^-/- p53^-/- controls (Reijns et al., 2012) and complemented Rnaseh2b^-/- p53^-/- MEFs (5 × 10^4 cells per well), were plated on coverslips in 6-well plates. After 24 h, non-chromatin bound proteins were extracted using pre-extraction buffer (25 mM HEPES...
pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl₂, 0.3 M sucrose, and 0.5% Triton X-100) for 7 min on ice. Cells were fixed with 4% PFA for 14 min at room temperature (RT). After blocking with 3% FCS in PBS for 30 min at RT, 53BP1 antibody (NB100-904, Novus Biologicals) was added for 1 h at RT. The next day, Alexa Fluor 568 goat anti-rabbit secondary antibody (Life technologies) was applied and incubated for 1 h at RT. Coverslips were mounted using Vectashield antifade mounting medium with DAPI (Vector laboratories) and imaged at RT using a Coolsnap HQ CCD camera (Photometrics) and a Zeiss Axioplan II fluorescence microscope with Plan-neofluar objectives (×40 and ×63) and acquired with iVision software (BioVision Technologies). Scoring was done under blinded conditions.

**Statistical analysis**

Data were analysed by unpaired t-test for normally distributed quantitative data and Mann–Whitney U-tests for nonparametric data as indicated in the text. One-sample t-tests were employed where parametric data were plotted in terms of percentage of control. Prism (GraphPad Software, Inc) was used throughout.

**Expanded View** for this article is available online.

**Acknowledgements**

We thank J. Dorin, D. Hunt, J. Rehwinkel, F. Semple and W. Bikmore for helpful discussions and Y. Crow, J. Cambier, J. Rehwinkel, J. Dorin, F. Semple, E. Hall, I. Stancheva and A. Wood for generous sharing of reagents. We thank the IGMM Transgenic Facility. E. Freyer and J. Ding for technical assistance. This work was funded by the MRC, Newlife Foundation for Disabled Children and The Wellcome Trust-University of Edinburgh ISSF2.

**Author contributions**

KJM, PC, LL, ZT, RER, BR, FK, AF, PSD, MAMR performed the experiments. KJM, PC, LL, ZT, EA, RER, BR, CG, MAMR and AP] analysed data. FD, AR and AF developed protocols and provided reagents. KJM, KR, RER, MAMR and AP] planned the project/supervised experiments. KJM, MAMR and AP] wrote the manuscript.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**References**


is the metazoan second messenger produced by DNA-activated cyclic
of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases.
Proc Natl Acad Sci USA 112: E5699–E5705
is required for lethal autoimmune disease in the Trex1-deficient mouse
V, Chara O, Lee YA, Hubner N, Bicknell L, Blum S, Krug C, Schmidt F,
Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S,
Hiller B, Achleitner M, Glage S, Naumann R, Behrendt R, Roers A,
T, Barnes DE (2004) Gene-targeted mice lacking the Trex1 (DNome III) 3’–
 reviewed the reverse transcriptase-RNase H: from viruses
Lenz LL (2011) MPYS is required for IFN response factor 3 activation and
the type I IFN production in the response of cultured phagocytes to bacterial
second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol 187:
2595–2601
Kailasan Vanaja S, Rathinam VA, Atianand MK, Kalantari P, Shehan B,
Fitzgerald KA, Leong JM (2014) Bacterial RNA:DNA hybrids are activators
of the NLRP3 inflammasome. Proc Natl Acad Sci U S A 111: 7765–7770
Kleinjan DA, Seawright A, Mella S, Carr CB, Tyas DA, Simpson TJ, Mason JO,
Price Dj, van Heyningen V (2006) Long-range downstream enhancers are
essential for Pax6 expression. Deu Biol 299: 563–581
Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U,
Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are
Liddicoat Bj, Piskol R, Chalk AM, Ramasswami G, Higuchi M, Hartner JC,
Li JB, Seeburg Pb, Walliker Cr (2015) RNA editing by ADAR1 prevents MDAS
sensing of endogenous dsRNA as nontself. Science 349: 1115–1120
Mankan AK, Schmidt T, Chauhan D, Goldeck M, Honing K, Gaidt M,
DNA hybrids activate the cGAS-STING axis. EMBO J 33: 2937–2946
Mannion NM, Greenwood SM, Young R, Cox S, Brindle J, Read D, Nellaker C,
Vesely C, Ponting CP, McLaughlin PJ, Jantsch MF, Dorin J, Adams IR,
Scaadden AD, Ohman M, Keegan LP, O’Connell MA (2014) The RNA-editing
enzyme ADAR1 controls innate immune responses to RNA. Cell Rep 9:
1482–1494
to antiviral defense. Anu N Y Acad Sci 1341: 126–135
Monti M, Stamp G, Robins P, Dulic A, Rosewell I, Hinvak C, Daly G, Lindahl
T, Barnes DE (2004) Gene-targeted mice lacking the Trex1 (DNome III) 3′–
>5′ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 24:
6719–6727
Pereira-Lopes S, Celhar T, Sans-Fons G, Serra M, Fairhurst AM, Lobeser J,
Celada A (2013) The exonuclease Trex1 restraints macrophage proinflammatory
Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid
sensor MDAS-driven autoimmunity and multi-organ development.
Immunity 43: 933–944
Rabe B (2013) Acardi-Goutieres syndrome: clues from the RNase H2 knock-
engineering using the CRISPR-Cas9 system. Nat Protoc 8: 2281–2308
Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, Liberator RA,
Bieniawz PD, Towers Cj, Moita Lf, Crow Yj, Bonthyn Df, Reis E Sousa C
(2013) SAMHD1-dependent retroviral control and escape in mice. EMBO J
32: 2454–2462.
Rejns MA, Bubeck D, Gibson LC, Graham SC, Baillie GS, Jones EY, Jackson AP
(2011) The structure of the human RNase H2 complex defines key
interaction interfaces relevant to enzyme function and human disease. J Biol Chem
286: 10530–10539
of ribonucleotides from DNA is essential for mammalian genome integrity
and development. Cell 149: 1008–1022
Rice GI, Bond J, Asipu A, Brunette RL, Manfield WW, Carr IM, Fuller JC, Jackson
SAMHD1 as regulator of the innate immune response. Nat Genet 41: 829–832
Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Sznzykiewicz M,
Dickerson J, Bhaskar SS, Zampini M, Briggs TA, Jenkinson EM, Bacinca CA,
Battini R, Bertini E, Brogan PA, Brumett LA, Carpenall M, De Laet C, de
Goutieres syndrome associated with a type I interferon signature. Nat Genet
44: 1243–1248
Rice GI, Forte GM, Sznzykiewicz M, Chase DS, Aebi A, Abdul-Hamid MS,
Ackroyd S, Allcock R, Bailey KM, Balottin U, Barneries C, Bernard G,
Bodemer C, Botella MP, Cereda C, Chandler KE, Dabeyden L, Dale RC, De
biomarkers in Acardi-Goutieres syndrome associated with mutations in
TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-
control study. Lancet Neurol 12: 1159–1169
Rice GI, del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G,
Bader-Meunier B, Baildam EM, Battini R, Beresford MW, Carasano M,
IFIH1 cause a spectrum of human disease phenotypes associated with
Revuelta A, Davidson DJ, Diebold S, Modis Y, MacDonald JS, Jackson AP
(2014) RNA:DNA hybrids are a novel molecular pattern sensed byTLR9.
EMBO J 33: 542–558
Ryder D, Game J (2002) Excision of misincorporated ribonucleotides in DNA
by RNase H (type 2) and FEN-1 in cell-free extracts. Proc Natl Acad Sci U S
A 99: 16654–16659

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.